TechFW member Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that CEO and Co-Founder Sulagna Bhattacharya has been named a winner of Ernst & Young’s Entrepreneur Of The Year® 2022 Central Plains Award.She is among 11 regional winners from 46 Central Plains finalists.
Entrepreneur Of The Year is one of the pre-eminent competitive business awards for entrepreneurs and leaders of high-growth companies. A panel of judges selected Bhattacharya based on her entrepreneurial spirit, purpose, growth, and impact, among other core contributions and attributes.
“I am honored to be named a winner in this competition by such a prestigious business organization alongside this dynamic group of business leaders making a difference in their respective fields,” said Bhattacharya. “This distinction is truly a win for the team at Nanoscope and reflects the passion and ingenuity we bring to work every day. It also underscores the tremendous progress we are making in the clinic advancing our ground-breaking platform of optogenetic therapies to restore blindness in people suffering from retinitis pigmentosa and other retinal diseases.”
Entrepreneur Of The Year celebrates entrepreneurs through regional and national awards programs in more than 145 cities throughout 60 countries. As a Central Plains award winner, Ms. Bhattacharya will be considered by the national judges for the Entrepreneur Of The Year 2022 National Awards.
Since 1986, EY US has celebrated the unstoppable entrepreneurs who are building a more equitable, sustainable and prosperous world for all. Entrepreneur Of The Year Award winners have exclusive, ongoing access to the experience, insight and wisdom of fellow alumni and other members of the entrepreneurial community in more than 60 countries — all supported by vast EY resources.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is in Phase 2b multi-center, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. Pre-clinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.
